Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 10/20 | 0.67 |
| ▸ | MME | P08473 | 6/20 | 0.67 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.67 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653010 | 1.00 | ECE1 (0.67) | ECE1MMEAGTR2ACP3 | |
| SCHEMBL8921308 | 0.93 | ECE1 (0.56) | ECE1MMEAGTR2ACP3 | |
| SCHEMBL8921295 | 0.93 | ECE1 (0.56) | ECE1MMEAGTR2ACP3 | |
| SCHEMBL8920954 | 0.87 | ECE1 (0.52) | ECE1MMEAGTR2ACP3 | |
| SCHEMBL8920944 | 0.87 | ECE1 (0.52) | ECE1MMEAGTR2ACP3 | |
| SCHEMBL8922277 | 0.86 | MME (0.51) | ECE1MMEAGTR2 | |
| SCHEMBL8922235 | 0.86 | MME (0.51) | ECE1MMEAGTR2 | |
| SCHEMBL8923646 | 0.85 | ECE1 (0.49) | ECE1MMEAGTR2ACP3 | |
| SCHEMBL8921710 | 0.85 | ECE1 (0.49) | ECE1MMEAGTR2ACP3 | |
| SCHEMBL8922631 | 0.84 | ECE1 (0.49) | ECE1MMEAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0660840-B1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | claimed |
| WO-1996026729-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES AS ECE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-09-06 | — | — | WO | claimed |
| US-5550119-A | ENDOTHELIN-CONVERTING ENZYM INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-08-27 | — | — | US | claimed |
| US-5273990-A | 5-Phosphonomethyleneamino aryl-substitued alkylene-1H-tetazoles | CIBA-GEIGY CORPORATION (US) | 1993-12-28 | — | — | US | claimed |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | disclosed |
| EP-0660840-B1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996026729-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES AS ECE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-09-06 | — | — | WO | disclosed |
| US-5550119-A | ENDOTHELIN-CONVERTING ENZYM INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0660840-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES. | CIBA GEIGY AG (CH) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994005677-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA-GEIGY AG (CH) | 1994-03-17 | — | — | WO | disclosed |
| US-5273990-A | 5-Phosphonomethyleneamino aryl-substitued alkylene-1H-tetazoles | CIBA-GEIGY CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ECE1 16/4885MME 1/4885AGTR2 11/4885 |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | AGTR2, REN, AGTR1 | ECE1 17/4885MME 4/4885AGTR2 1/4885 |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | ECE1 81/4885MME 1/4885AGTR2 42/4885 |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | ECE1 81/4885MME 1/4885AGTR2 40/4885 |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | ECE1 81/4885MME 1/4885AGTR2 40/4885 |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | MME, AGTR1, AGTR2 | ECE1 39/4885MME 1/4885AGTR2 3/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ECE1 10/4885MME 1/4885AGTR2 13/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | ECE1 12/4885MME 1/4885AGTR2 9/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | ECE1 16/4885MME 1/4885AGTR2 11/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | ECE1 10/4885MME 1/4885AGTR2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.